Effect of raloxifene on endometrial cancer risk in a population-based, case-control study

DeMichele, Angie; Troxel, A.; Weber, Arthur; Berlin, J.; Bunin, Greta R.; Turzo, Elene; Burgh, Desiree; Schinnar, Rita; Rubin, Steven J.; Rebbeck, Timothy R.; Strom, Brian

doi:10.1200/jco.2005.23.16_suppl.5001

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A newly published evaluation of data from the CORE trial demonstrated that raloxifene is not associated with a change in the incidence of uterine cancer, endometrial hyperplasia or postmenopausal bleeding, versus placebo, over 8 years of therapy [88]. However, raloxifene was associated with a 50% reduction in the incidence of endometrial cancer (RR: 0.50; 95% CI: 0.29–0.85), compared with untreated controls, in a recent abstract describing a large case–control study [89]. The RR of ovarian cancer was 0.5 in nearly 10,000 patients in randomized, controlled trials with raloxifene, but with only 16 total cases, this difference is not statistically significant [90].…”

Section: Effects Of Raloxifene On the Uterusmentioning

confidence: 99%

Raloxifene: A Selective Estrogen-Receptor Modulator for Postmenopausal Osteoporosis – a Clinical Update on Efficacy and Safety

Deal

Draper

2006

Womens Health (Lond Engl)

View full text Add to dashboard Cite

Selective estrogen-receptor modulators are molecules with specific estrogen-receptor binding affinity. Each selective estrogen-receptor modulator induces a unique conformation in the ligand-receptor complex, which leads to transcriptional activation and/or inhibition. Raloxifene 60 mg/day, a benzothiophene selective estrogen-receptor modulator, is approved for the prevention and treatment of postmenopausal osteoporosis. This article provides an update on new studies and further analyses of clinical trial data for raloxifene. The Multiple Outcomes of Raloxifene Evaluation (MORE) trial of women with osteoporosis has described the efficacy of raloxifene in decreasing vertebral fracture risk over 4 years. The Continuing Outcomes Relevant to Evista((R)) (CORE) trial, designed to assess the effects of raloxifene on breast cancer prevention, is a 4-year continuation of MORE. The skeletal and cardiovascular effects of raloxifene in the CORE study were similar to those observed in MORE. The relative risk of developing breast cancer was significantly decreased in women treated with raloxifene, compared with placebo, after 4 years in MORE and 8 years in the CORE trial. The incidence of uterine bleeding, endometrial hyperplasia and endometrial cancer was similar between raloxifene and placebo after 8 years of treatment. Raloxifene use is associated with a higher incidence of hot flashes and leg cramps, and an increased risk of venous thromboembolic events.

show abstract

Section: Effects Of Raloxifene On the Uterusmentioning

confidence: 99%

Raloxifene: A Selective Estrogen-Receptor Modulator for Postmenopausal Osteoporosis – a Clinical Update on Efficacy and Safety

Deal

Draper

2006

Womens Health (Lond Engl)

View full text Add to dashboard Cite

show abstract

“…5001 [7]. La prise de raloxifène diminuait de 47 % le risque de développer un adéno-carcinome de l'endomètre, alors que la prise de tamoxifène augmentait ce risque de 53 %.…”

Section: Cancer De L'endomètre Traitement Préventif (Abst 5001)unclassified

Cancers gynécologiques

Petit¹

2005

Oncologie

View full text Add to dashboard Cite

“…[11] • Statins may protect women from developing breast cancer according to a case control study involving over 40 000 patients. [13] [12] • Raloxifene may confer protection against endometrial cancer, with data indicating a benefit of 50% in users of raloxifene versus nonusers.…”

Section: Advances In Cancer Prevention Highlightedmentioning

confidence: 99%

American Society of Clinical Oncology

Pochon¹

2005

International Journal of Pharmaceutical Medicine

View full text Add to dashboard Cite

The annual meeting of the American Society of Clinical Oncology (ASCO) was an international 5-day event that attracted in excess of 29 000 delegates from the field of oncology. This year's theme -'Advancing the Science of Clinical Oncology' -was a reflection of the ground-breaking research that has been conducted in the field of oncology in the last few years and placed great emphasis on the importance of targeted therapies, molecular diagnostics, genomics and proteomics -specialties that are rapidly becoming an essential component in the daily practice of clinical oncologists. Great strides have also been made in the three most common cancers, breast, lung and colorectal, as well as promising data presented in cancers that have to date offered a poor prognosis to patients, such as prostate and pancreatic cancer.Such was the volume of first-class research covered at this year's meeting that rather than the traditional single plenary session, delegates were invited to attend three such sessions, to cover presentations that the ASCO Scientific Program Committee considered to have practice-changing consequences. 1Generally hailed as the most exciting session at this year's meeting was a late addition to the ASCO programme, added just two weeks before the event. The 'Advances in Monoclonal Antibody Therapy for Breast Cancer' session ended with a standing ovation from the audience in recognition of the exciting new developments and impressive results that were presented.

show abstract

Effect of raloxifene on endometrial cancer risk in a population-based, case-control study

Cited by 4 publications

References 0 publications

Raloxifene: A Selective Estrogen-Receptor Modulator for Postmenopausal Osteoporosis – a Clinical Update on Efficacy and Safety

Raloxifene: A Selective Estrogen-Receptor Modulator for Postmenopausal Osteoporosis – a Clinical Update on Efficacy and Safety

Cancers gynécologiques

American Society of Clinical Oncology

Contact Info

Product

Resources

About